A detailed history of Barclays PLC transactions in Regulus Therapeutics Inc. stock. As of the latest transaction made, Barclays PLC holds 84,477 shares of RGLS stock, worth $143,610. This represents 0.0% of its overall portfolio holdings.

Number of Shares
84,477
Previous 84,477 -0.0%
Holding current value
$143,610
Previous $132,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$1.46 - $1.9 $91,321 - $118,843
62,549 Added 285.25%
84,477 $132,000
Q2 2024

Aug 14, 2024

BUY
$1.79 - $2.8 $39,251 - $61,398
21,928 New
21,928 $40,000
Q2 2023

Aug 03, 2023

BUY
$0.87 - $1.75 $191 - $385
220 Added 4400.0%
225 $0
Q1 2023

May 04, 2023

BUY
$0.79 - $1.61 $3 - $8
5 New
5 $0

Others Institutions Holding RGLS

About Regulus Therapeutics Inc.


  • Ticker RGLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 14,634,400
  • Market Cap $24.9M
  • Description
  • Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-thre...
More about RGLS
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.